Last reviewed · How we verify
PPV23 vaccination or PCV13 vaccination
At a glance
| Generic name | PPV23 vaccination or PCV13 vaccination |
|---|---|
| Also known as | Prevenar 13, Pneumovac 23 |
| Sponsor | AZ Sint-Jan AV |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy (PHASE2)
- Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease (PHASE4)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) (PHASE3)
- Pneumococcal Conjugate Vaccine in Aging Renal Transplant (EARLY_PHASE1)
- Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines (PHASE3)
- Influenza Vaccine and Pneumococcal Vaccine (PHASE4)
- Pneumonia Vaccine in Aging HIV Positive Individuals (EARLY_PHASE1)
- 13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PPV23 vaccination or PCV13 vaccination CI brief — competitive landscape report
- PPV23 vaccination or PCV13 vaccination updates RSS · CI watch RSS
- AZ Sint-Jan AV portfolio CI